Pear and BrightView expand digital treatment pilot

  • January 30, 2023
  • William Payne

Prescription digital therapeutics specialist Pear Therapeutics is expanding its collaboration with addiction treatment provider BrightView Health. Brightview provides evidence-based, outpatient addiction treatment programmes. The collaboration will provide digital therapeutic treatments, reSET and reSET-O, to eligible adults suffering from substance use disorder (SUD) and opioid use disorder (OUD).

BrightView began piloting Pear’s products in its centres across six locations in Kentucky and Ohio in early 2022. It intends to expand the initiative across Kentucky, Ohio, Delaware, Massachusetts, and Virginia. BrightView currently has over 80 locations across 8 states.

The two products being piloted by BrightView — reSET and reSET-O — have been measured in real-world use and their therapeutic content studied in randomised controlled trials, with results published in peer-reviewed medical journals. Additionally, Pear has released publications showing the potential for improved real-world health outcomes and decreased treatment costs for patients using reSET and reSET-O. reSET is used as a monotherapy for patients 18 years of age or older with substance use disorder and reSET-O is used in combination with buprenorphine-based medication assisted treatment for patients 18 years of age or older with opioid use disorder. Clinicians receive access to clinical dashboards to inform visits with patients.

“We strive to make recovery work for patients and to meet them where they are,” said Shawn Ryan, MD, MBA, ABEM, ABAM, Chief Science Officer, of BrightView Health. “We believe reSET and reSET-O are beneficial to our patients, the community, and our health system. BrightView plans to continue expanding our use of Pear’s PDTs to help patients achieve progress in recovery.”

Substance use disorders are a major public health crisis affecting communities across the country. In 2020 alone, drug overdose deaths in Kentucky increased by nearly 50%, with a state report concluding that isolation caused by the pandemic was a major contributing factor. According to RecoveryOhio’s annual review from 2021, 10-15% of all Ohioans have a life history of substance use disorder. Pear and BrightView are working together to help improve access to care for those affected by this national epidemic.

“As the severity of the addiction crisis continues to increase, Pear is proud to be working with BrightView to provide innovative treatments to Kentuckians and Ohioans,” said Julia Strandberg, Chief Commercial Officer of Pear. “We look forward to expanding these efforts and engaging new patients.”